Semaglutide dosage chart

Reconstitution steps

1. 1Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. 2Inject slowly down the vial wall to minimize foaming; avoid shaking.
3. 3Gently swirl or roll the vial until the powder is fully dissolved.
4. 4Label the vial with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
5. 5Use reconstituted solution within 28 days for maximum potency and safety.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a proper sharps container.
• Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and avoid lipohypertrophy.
• Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
• Administer on the same day each week for consistency; if a dose is missed, take it as soon as possible within 5 days of the missed dose.
• GLP-1 receptor agonists may cause gastrointestinal side effects (nausea, vomiting); gradual dose escalation helps minimize these effects.
• The 20 mg vial size provides excellent economy for weekly dosing, with a single vial lasting 16+ weeks through the escalation phase.

How This Works

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. It promotes weight loss through multiple mechanisms: reducing appetite and food intake via central nervous system effects, slowing gastric emptying, and improving glycemic control through glucose-dependent insulin secretion. The extended half-life of approximately 7 days is due to albumin binding and resistance to DPP-4 degradation, enabling convenient once-weekly dosing. Clinical trials have demonstrated significant weight loss (mean 10–15% body weight reduction) in individuals with obesity when combined with lifestyle interventions. The weekly 2.4 mg maintenance dose is FDA-approved for chronic weight management and represents the standard clinical approach.

Potential Benefits & Side Effects

Observations from clinical literature and regulatory approvals.

• Significant weight loss (mean 10–15% body weight reduction in clinical trials at 2.4 mg weekly dose) when combined with lifestyle modifications.
• Improved glycemic control through enhanced glucose-dependent insulin secretion and reduced glucagon secretion.
• Reduced appetite and food intake via central nervous system GLP-1 receptor activation.
• Cardiovascular benefits demonstrated in outcome trials, including reduced risk of major adverse cardiovascular events.
• Convenient once-weekly dosing improves adherence compared to daily regimens.
• Gastrointestinal effects (most common): nausea, vomiting, diarrhea, constipation, abdominal pain—typically mild to moderate and decreasing with gradual dose escalation.
• Injection-site reactions: redness, swelling, or irritation (generally mild and transient).
• Hypoglycemia risk (when combined with insulin or sulfonylureas)—less common with Semaglutide monotherapy due to glucose-dependent mechanism.
• Rare serious adverse events: pancreatitis, gallbladder disease, acute kidney injury; thyroid C-cell tumors observed in rodent studies (relevance to humans uncertain).

Lifestyle Factors

Complementary strategies for optimal outcomes with GLP-1 therapy.

• Maintain a balanced, calorie-controlled diet with adequate protein intake (1.2–1.6 g/kg body weight) to preserve lean muscle mass during weight loss.
• Combine regular physical activity including both resistance training (2–3 days per week) and aerobic exercise (150+ minutes per week) to reinforce metabolic adaptations and improve body composition.
• Prioritize consistent sleep (7–9 hours nightly) and effective stress management to support adherence and metabolic health.
• Stay well-hydrated (8–10 glasses of water daily), especially if experiencing gastrointestinal side effects.
• Monitor progress through regular weigh-ins, body measurements, photos, and consultation with healthcare providers.
• Consider working with a registered dietitian for personalized nutrition guidance during weight loss.

Injection Technique

General subcutaneous injection guidance from clinical best-practice resources.

• Clean the vial stopper and chosen skin site with separate alcohol swabs; allow both to dry completely before proceeding.
• Pinch a fold of skin between your fingers; insert the needle at a 45–90° angle into the subcutaneous tissue (fatty layer, not muscle).
• Do not aspirate (pull back the plunger) when giving a subcutaneous injection.
• Inject the solution slowly and steadily; wait at least 6 seconds after injection before withdrawing the needle to ensure complete delivery and minimize leakage.
• Withdraw the needle and apply light pressure with a clean swab; avoid rubbing vigorously.
• Rotate injection sites systematically (abdomen, thighs, upper arms) with each weekly injection to prevent lipohypertrophy and maintain consistent absorption. The abdomen is the preferred site for most consistent absorption.
• Dispose of used syringes and needles immediately in a proper FDA-approved sharps container.

important-note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Semaglutide is a prescription medication in many jurisdictions. This protocol is for educational purposes only. Always consult qualified healthcare professionals before starting any peptide protocol.

Semaglutide dosage FAQs